摘要
目的探讨提高患者对蒽环类药物心脏毒性耐受性的途径。方法回顾性分析81例乳腺恶性肿瘤患者的临床资料,比较复方苦参注射液及参芪扶正注射液对乳腺恶性肿瘤患者蒽环类药物多疗程化学治疗所致心脏不良反应,观察不良反应发生情况并判定疗效。结果复方苦参注射液组、参芪扶正注射液组心功能及心电图异常的发生率、心肌酶数值升高均小于对照组,同时较对照组心功能、心电图及心肌酶有明显改善(P<0.05)。结论复方苦参注射液及参芪扶正注射液对心脏具有一定保护作用,能降低蒽环类药物心脏毒性,提高患者的耐受性,特别是多疗程化疗后的患者受益更加明显。
Objective To investigate the pathway for increasing the patient＇s tolerance to anthracycline- induced cardiac toxicity.Methods The clinical data in 81 cases of malignant breast tumor were retrospectively analyzed. The effects of Compound Kushen Injection and Shenqifuzheng Injection for treating the cardiac adverse reactions caused the multiple chemotherapy of anthracyclines in the patients with malignant breast tumor were observed and evaluated. Results The occurrence rate of heart function and EKG abnormality,and increased values of myocardial enzymes in the Compound Kushen Injection group and the Shenqifuzheng Injection group were less than those in the control group. In the Compound Kushen injection group and the Shenqifuzheng injection group,the cardiac function and incidence of abnormal electrocardiogram were lower than that in the control group. At the same time,the heart function,EKG and myocardial enzymes in the these two groups were significantly improved compared with the control group. Conclusion Compound Kushen Injection and Shenqifuzheng Injection possess certain protective effect on heart,which can reduce the anthracycline- induced cardiac toxicity,increase the patient＇s tolerance,especially the patients with multiple courses of chemotherapy receive more benefits.
出处
《中国药业》
CAS
2014年第24期124-126,共3页
China Pharmaceuticals
基金
江苏省自然科学基金资助项目
项目编号:BK20130432
江苏省扬州市社会发展科技攻关项目
项目编号:SGG201230119
